Cano Health Provides First Quarter 2021 Business Update
News provided by
Share this article
Share this article
MIAMI, June 9, 2021 /PRNewswire/ Cano Health, Inc. (NYSE: CANO), a leading value-based primary care provider for seniors and underserved communities, today announced business and financial results for the first quarter ended March 31, 2021, prior to the closing on June 3, 2021 of the recent business combination between Cano Health and Jaws Acquisition Corp.
First Quarter 2021 Financial Results
$280.1 million total revenue, up 107% from the prior-year period
116,895 members, a 91% increase from the prior-year period. Organic membership increased 43% from the prior-year period
Net loss of $10.5 million
$22.8 million Adjusted EBITDA, up 77% from the prior-year period. Adjusted EBITDA margin of 8.1% compared to 9.5% in the prior-year period
Share this article
Share this article
NEW BRUNSWICK, N.J., June 9, 2021 /PRNewswire/ Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at
8:30 a.m. (Eastern Time) on Wednesday, July 21
stto review second-quarter results. Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Christopher DelOrefice, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include Alex Gorsky, Chairman and Chief Executive Officer.
Investors and other interested parties can access the webcast/conference call in the following ways:
The webcast and presentation material are accessible at Johnson & Johnson s website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.
/PRNewswire/ The "Cell-based Assays Market" report has been added to SpendEdge s library which is trusted by more than 100 CPOs and 500 category managers.
Vuzix Smart Glasses Expand AR Surgical Product Presence to Support Shoulder, Knee and Spine Surgeries
- NextAR surgical AR platform developed by Medacta International receives CE marking for knee, shoulder and spine applications.
- NextAR surgical AR platform receives US Food and Drug Administration (FDA) clearance for shoulder application.
News provided by
Share this article
Share this article
ROCHESTER, N.Y., June 9, 2021 /PRNewswire/ Vuzix® Corporation (NASDAQ: VUZI), ( Vuzix or, the Company ), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced the market expansion to support the NextAR surgical AR platform developed by Medacta International, one of the world s largest providers of innovative orthopedic products focusing on healthcare sustainability. Having used the Vuzix Blade to complete the first smart glasses-based total knee replacement in the US in 2020, Medacta recently received its CE marking for knee, sho
/PRNewswire/ AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their.